Abstract
Clinical trials that tested the antitumor activity of γδ T cells have been mostly unsuccessful. To address this, we expanded human Vγ9Vδ2 T cells in TGFβ1, a cytokine which enhances their viability, trafficking properties, and intrinsic antitumor activity. This protocol summarizes the production and in vitro functional characterization of TGFβ1 educated human Vγ9Vδ2 cells and highlights their compatibility with chimeric antigen receptor (CAR) engineering. We also describe in vivo testing of the antitumor activity of these CAR T cells in mice.
For complete details on the use and execution of this protocol, please refer to Beatson et al. (2021).
TGFβ promotes viability and retards differentiation of Vγ9Vδ2 cells
TGFβ-educated Vγ9Vδ2 cells achieve greater invasion and anticancer activity
Specificity of these cells can be reprogrammed using chimeric antigen receptors
Collapse